KR20140033432A - (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체 - Google Patents

(s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체 Download PDF

Info

Publication number
KR20140033432A
KR20140033432A KR1020137033590A KR20137033590A KR20140033432A KR 20140033432 A KR20140033432 A KR 20140033432A KR 1020137033590 A KR1020137033590 A KR 1020137033590A KR 20137033590 A KR20137033590 A KR 20137033590A KR 20140033432 A KR20140033432 A KR 20140033432A
Authority
KR
South Korea
Prior art keywords
cancer
compound
ray powder
powder diffraction
polymorph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137033590A
Other languages
English (en)
Korean (ko)
Inventor
이자벨 실비 잘루
코르넬리우스 가우어
프랭크 스토바서
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140033432A publication Critical patent/KR20140033432A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137033590A 2011-06-21 2012-06-19 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체 Withdrawn KR20140033432A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499222P 2011-06-21 2011-06-21
US61/499,222 2011-06-21
PCT/EP2012/061756 WO2012175522A1 (en) 2011-06-21 2012-06-19 Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide

Publications (1)

Publication Number Publication Date
KR20140033432A true KR20140033432A (ko) 2014-03-18

Family

ID=46319784

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137033590A Withdrawn KR20140033432A (ko) 2011-06-21 2012-06-19 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체

Country Status (11)

Country Link
US (1) US9006270B2 (enExample)
EP (1) EP2723733A1 (enExample)
JP (1) JP2014517049A (enExample)
KR (1) KR20140033432A (enExample)
CN (1) CN103619840B (enExample)
BR (1) BR112013032687A2 (enExample)
CA (1) CA2839621A1 (enExample)
IN (1) IN2014DN00145A (enExample)
MX (1) MX2013014887A (enExample)
RU (1) RU2014101626A (enExample)
WO (1) WO2012175522A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220045883A (ko) 2020-10-06 2022-04-13 엘지디스플레이 주식회사 전송 장치 및 표시 시스템

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
KR20150002623A (ko) * 2012-03-30 2015-01-07 노파르티스 아게 신경모세포종, 유잉 육종 또는 횡문근육종의 치료에 사용하기 위한 화합물
CA2930359C (en) * 2013-12-06 2022-03-01 Novartis Ag Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CA2962714C (en) * 2014-10-03 2023-09-19 Novartis Ag Pharmaceutical compositions comprising alpelisib
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
CN112961090A (zh) * 2019-12-13 2021-06-15 武汉九州钰民医药科技有限公司 合成Alpelisib的关键中间体及其制备方法
CN111057051A (zh) * 2019-12-16 2020-04-24 武汉九州钰民医药科技有限公司 PI3K抑制剂Alpelisib的新合成方法
CN110964005A (zh) * 2019-12-16 2020-04-07 武汉九州钰民医药科技有限公司 一种Alpelisib的制备工艺
WO2022234408A1 (en) * 2021-05-03 2022-11-10 Novartis Ag Alpelisib formulation
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
EP2016075A1 (en) * 2006-05-03 2009-01-21 AstraZeneca AB Thiazole derivatives and their use as anti-tumour agents
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220045883A (ko) 2020-10-06 2022-04-13 엘지디스플레이 주식회사 전송 장치 및 표시 시스템

Also Published As

Publication number Publication date
MX2013014887A (es) 2014-02-17
RU2014101626A (ru) 2015-07-27
US9006270B2 (en) 2015-04-14
IN2014DN00145A (enExample) 2015-05-22
JP2014517049A (ja) 2014-07-17
CA2839621A1 (en) 2012-12-27
EP2723733A1 (en) 2014-04-30
AU2012274141B2 (en) 2015-12-24
AU2012274141A1 (en) 2013-12-12
CN103619840B (zh) 2016-01-20
WO2012175522A1 (en) 2012-12-27
US20140171470A1 (en) 2014-06-19
CN103619840A (zh) 2014-03-05
BR112013032687A2 (pt) 2016-08-30

Similar Documents

Publication Publication Date Title
KR20140033432A (ko) (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
JP5611959B2 (ja) Ｃ型肝炎ウイルス阻害剤
KR20240101561A (ko) Kras의 저해제로서의 퀴놀린 화합물
EP3008039B1 (en) Crystalline form of a mdm2 inhibitor
JP5596861B2 (ja) Ｃ型肝炎ウイルス阻害剤
CA3199074A1 (en) Compounds and methods for the targeted degradation of androgen receptor protein
CN116490184B (zh) 用于抑制egfr突变癌症的化合物及其药物用途
JP2020528918A (ja) アンドロゲン受容体の標的化分解のための化合物および方法
EP3322409A1 (en) Substituted aza compounds as irak-4 inhibitors
CA2940918C (en) Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-.alpha.]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-.alpha.][1,4]diazepine derivatives as ros1 inhibitors
CN110678462B (zh) Mdm2-p53相互作用的异吲哚啉酮抑制剂和其制造方法
EA022384B1 (ru) Ингибиторы вируса гепатита c
KR20120133366A (ko) Ｃ형 간염 바이러스 억제제
CA2974367A1 (en) Compounds and methods for the targeted degradation of the androgen receptor
EA019976B1 (ru) Ингибиторы вируса гепатита с
KR20210049895A (ko) 고 활성 sting 단백질 작용제 화합물
JP6895396B2 (ja) 疾患を処置するためのｇｌｓ１阻害薬
WO2012003829A1 (en) Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
WO2019158070A1 (zh) A2a和/或a2b受体拮抗剂
CN103402995A (zh) 新型吲哚、吲唑衍生物或其盐
CN119585275A (zh) 恢复p53突变功能的化合物及其应用
CA3240229A1 (en) Novel hdac inhibitors and therapeutic use thereof
AU2020413555B2 (en) PD-L1 antagonist compound
AU2012274141B8 (en) Polymorphs of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide
CN109415371B (zh) 一种2-酰氨基噻唑衍生物及其制备方法与用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131218

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid